112 related articles for article (PubMed ID: 16765240)
1. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease.
Rehring TF; Stolcpart RS; Sandhoff BG; Merenich JA; Hollis HW
J Vasc Surg; 2006 Jun; 43(6):1205-10. PubMed ID: 16765240
[TBL] [Abstract][Full Text] [Related]
2. Atherosclerotic risk factor control in patients with peripheral arterial disease.
Rehring TF; Sandhoff BG; Stolcpart RS; Merenich JA; Hollis HW
J Vasc Surg; 2005 May; 41(5):816-22. PubMed ID: 15886666
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a pharmacy care management program for veterans with dyslipidemia.
Smith MC; Boldt AS; Walston CM; Zillich AJ
Pharmacotherapy; 2013 Jul; 33(7):736-43. PubMed ID: 23625745
[TBL] [Abstract][Full Text] [Related]
4. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey.
Sukonthasarn A; Homsanit M; Prommete B; Chotinaiwattarakul C; Piamsomboon C; Likittanasombat K
J Med Assoc Thai; 2011 Dec; 94(12):1424-34. PubMed ID: 22295727
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients discharged from pharmacy-managed cardiovascular disease management.
Olson KL; Delate T; Rasmussen J; Humphries TL; Merenich JA;
Am J Manag Care; 2009 Aug; 15(8):497-503. PubMed ID: 19670953
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lipid management in patients with coronary versus peripheral arterial disease.
Sharma S; Thapa R; Jeevanantham V; Myers T; Hu C; Brimacombe M; Vacek JL; Dawn B; Gupta K
Am J Cardiol; 2014 Apr; 113(8):1320-5. PubMed ID: 24560066
[TBL] [Abstract][Full Text] [Related]
8. Lipid management in high risk coronary patients: how effective are we at secondary intervention?
Zhu YY; Hayward PA; Hare DL; Stewart AG; Buxton BF
Heart Lung Circ; 2012 Feb; 21(2):82-7. PubMed ID: 22153966
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic.
Pirro M; Del Giorno R; Lupattelli G; Mannarino MR; Roscini AR; Covelli D; Schillaci G; Pasqualini L; Bagaglia F; Siepi D; Mannarino E
Eur J Intern Med; 2011 Aug; 22(4):412-7. PubMed ID: 21767761
[TBL] [Abstract][Full Text] [Related]
10. Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization.
Olson KL; Rasmussen J; Sandhoff BG; Merenich JA;
Arch Intern Med; 2005 Jan; 165(1):49-54. PubMed ID: 15642874
[TBL] [Abstract][Full Text] [Related]
11. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease.
Feringa HH; Karagiannis SE; van Waning VH; Boersma E; Schouten O; Bax JJ; Poldermans D
J Vasc Surg; 2007 May; 45(5):936-43. PubMed ID: 17360142
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
Petrella RJ; Merikle E; Jones J
Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
[TBL] [Abstract][Full Text] [Related]
13. Lipid profile in patients with coronary artery disease.
Haddad FH; Omari AA; Shamailah QM; Malkawi OM; Shehab AI; Mudabber HK; Shubaki MK
Saudi Med J; 2002 Sep; 23(9):1054-8. PubMed ID: 12370711
[TBL] [Abstract][Full Text] [Related]
14. Achieving cholesterol target in a managed care organization (ACTION) trial.
Straka RJ; Taheri R; Cooper SL; Smith JC
Pharmacotherapy; 2005 Mar; 25(3):360-71. PubMed ID: 15843283
[TBL] [Abstract][Full Text] [Related]
15. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers.
Mazzolini TA; Irons BK; Schell EC; Seifert CF
J Manag Care Pharm; 2005; 11(9):763-71. PubMed ID: 16300420
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
17. Dyslipidemia control in indigent patients receiving medication assistance compared with insured patients.
Marrs JC; Saseen JJ
Pharmacotherapy; 2008 May; 28(5):562-9. PubMed ID: 18447654
[TBL] [Abstract][Full Text] [Related]
18. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
Sorensen SV; Frick KD; Wade A; Simko R; Burge R
Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
[TBL] [Abstract][Full Text] [Related]
19. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting.
Till LT; Voris JC; Horst JB
J Manag Care Pharm; 2003; 9(3):269-73. PubMed ID: 14613471
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a pharmacist-managed telephone lipid clinic at a Veterans Affairs Medical Center.
Fabbio KL; Bradley M; Chrymko M
Ann Pharmacother; 2010 Jan; 44(1):50-6. PubMed ID: 20028961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
